Januvia
Similar to Byetta, Januvia is also an injectable drug used to treat patients with type 2 diabetes. However Januiva is not a GLP-1 therapy, but rather the first in a class of drugs called dipeptidyl peptidase-4 (DPP-4) inhibitors.
Despite their differences, both Januvia and Byetta have been linked to serious complications such as pancreatitis. Certain studies have found that compared to other treatments, users of Januvia have a six-fold increased risk of developing pancreatitis, and a 2.7-fold increased risk of developing pancreatic cancer.
If you have taken Januvia and suffered serious side effects, contact a Januvia attorney with Kirkendall Dwyer LLP today. We can give you the immediate answers that you need. Other patients like you have recovered compensation for their injuries. To find out if you too may qualify, contact us today.
Blog Posts
Merck to Stop Distributing Diabetes and Cholesterol Combination Medication
Merck, manufacturer of the controversial diabetes drug Januvia, has made the decision to stop manufacturing a combination of Januvia (sitagliptin) and the high cholesterol treatment simvastatin. The drug was called Juvisync, and the theory behind it was that the company could increase profits by capitalizing on the large population of individuals that suffer from high…
Onglyza Linked to Increased Risk of Heart Failure
Onglyza, a DPP-4 inhibitors, was the subject of a new study conducted by researchers at the Brigham and Women’s Hospital in Boston. The study concluded with the following findings: Onglyza resulted in an increased risk of heart failure. Those taking the diabetes medication had a 3.5% increased risk, versus 2.8% in the control group. There…
Incretin Mimetic Drug Lawsuits Consolidated in Federal Court
On August 28, 2013, it was announced that litigation involving incretin mimetic drugs Byetta, Victoza, Januvia, and Janumet are being consolidated into multi-district litigation in California federal court. Usually lawsuits against different companies, as is in this case, are not consolidated into one MDL. In this case however, many of the plaintiffs bringing the lawsuits…
